Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Bristol myers Squibb Company
Bristol myers Squibb Company And Lexicon Pharmaceuticals Inc
Bristol myers Squibb Company And Albany Molecular Research Inc
Bristol myers Squibb Company_20100107
Bristol myers Squibb Company_20100121
Bristol myers Squibb Company_20131212
Bristol myers Squibb Company_20100128
Bristol myers Squibb Company_20100114
  

Bristol myers Squibb Company patents

Recent patent applications related to Bristol myers Squibb Company. Bristol myers Squibb Company is listed as an Agent/Assignee. Note: Bristol myers Squibb Company may have other listings under different names/spellings. We're not affiliated with Bristol myers Squibb Company, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Bristol myers Squibb Company-related inventors




Date Bristol myers Squibb Company patents (updated weekly) - BOOKMARK this page
07/20/17 new patent  Apixaban formulations
07/20/17 new patent  Apixaban formulations
07/20/17 new patent  Dosage forms of apixaban
07/06/17Modified fgf-21 polypeptides and uses thereof
07/06/17Bsl2v2c2-ig polypeptides
07/06/17Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
06/29/17Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production
06/29/17Biaryl kinase inhibitors
06/29/17Stabilized fibronectin based scaffold molecules
06/22/17Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
06/22/176h-furo[2,3-e]indole compounds for the treatment of hepatitis c
06/22/17Serum albumin-binding fibronectin type iii domains
06/22/17Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
06/15/17Five-membered heterocycles useful as serine protease inhibitors
06/15/17Fibronectin based scaffold proteins having improved stability
06/08/17Novel macrocycles as factor xia inhibitors
06/08/17Ip-10 antibodies and their uses
06/08/17Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
06/01/17Carbazole compounds useful as bromodomain inhibitors
05/25/17Compositions comprising a combination of an anti-pd-1 antibody and another antibody
05/25/17Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
05/25/17Serum albumin binding molecules
05/18/17Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
05/18/17Imidazo-pyridazine derivatives as casein kinase 1 delta/epsilon inhibitors
05/18/17Fibronectin binding domains with reduced immunogenicity
05/18/17Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
05/11/17Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
05/11/17Mammalian cell culture processes for protein production
05/11/17Mammalian cell culture processes for protein production
05/04/17Polycyclic lpa1 antagonist and uses thereof
05/04/17Substituted 2-phenyl (aza)benzofuran compounds for the treatment of hepatitis c
04/27/17Substituted pyridinones as mgat2 inhibitors
04/20/17Compounds useful as immunomodulators
04/13/172-(aryl- or heteroaryl-)phenyl (aza)benzofuran compounds for the treatment of hepatitis c
04/06/17Macrocycles with aromatic p2' groups as factor xia inhibitors
03/30/17Fibronectin based scaffold domain proteins that bind to myostatin
03/30/17Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
03/23/17Pyrrolidine gpr40 modulators
03/23/17Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
03/16/17Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
03/16/17Benzodiazepine dimers, conjugates thereof, and methods of making and using
03/09/17(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
03/09/17Indole carboxamide compounds
03/02/17Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
03/02/17Macrocyclic factor xia inhibitors condensed with heterocycles
02/23/17Methods for maintaining pegylation of polypeptides
02/23/17Lactam-containing compounds and derivatives thereof as factor xa inhibitors
02/23/17Methods of treating transplant rejection using a domain antibody directed against cd40
02/16/17Substituted bicyclic compounds
02/09/17Fibronectin binding domains with reduced immunogenicity
02/09/17Method of treating cancer using immune checkpoint inhibitor
02/02/17Modified fgf-21 polypeptides comprising an internal deletion and uses thereof
02/02/17Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
01/26/17Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
01/26/17Il-23 antibodies and methods of using the same
01/19/17Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
01/19/17Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders
01/19/17Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
01/19/17Antibody polypeptides that antagonize cd40
01/12/17Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
01/12/17Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
01/05/17Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
12/29/16Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
12/29/16Iap antagonists
12/29/16Fc fusion proteins comprising novel linkers or arrangements
Patent Packs
12/29/16Antibodies to cd40 with enhanced agonist activity
12/22/16Pyrimidinones as factor xia inhibitors
12/22/16Fully human antibodies against human 4-1bb
12/15/16Quinazolines as potassium ion channel inhibitors
12/15/16Macrocycles as factor xia inhibitors
12/15/16Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
12/08/164-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists
12/08/16Method of using antibody polypeptides that antagonize cd40 to treat ibd
12/01/16Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
12/01/16Antibodies against ox40 and uses thereof
12/01/16Antibodies that bind novel pcsk9 variants
11/24/16Hepatitis c virus inhibitors
11/24/16Dihydropyridone p1 as factor xia inhibitors
11/24/16Process for the preparation of cycloheptapyridine cgrp receptor antagonists
11/24/16Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions
Patent Packs
11/24/16Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
11/17/16Quinoline-based kinase inhibitors
11/17/16Aryl lacta kinase inhibitors
11/17/16Tricyclic compounds as anticancer agents
11/10/16Process for the synthesis of chiral propargylic alcohols
11/10/16Cyclohexyl sulfone ror gamma modulators
11/10/16Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators
11/10/16Heterocyclic sulfone ror gamma modulators
11/10/16Sulfone amide linked benzothiazole inhibitors of endothelial lipase
11/10/16Novel tricyclic compounds as anticancer agents
11/10/16Tricyclic sulfones as rory modulators
11/10/16Anti-lag-3 antibodies to treat hematological malignancies
11/03/16Rory modulators
11/03/16Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
11/03/16A novel compound for the treatment of hepatitis c
11/03/16Tricyclic compounds as anticancer agents
10/27/16Hepatitis c virus inhibitors
10/27/164,4'-biphenyldiyl-bis-(1 h-imidazolyl) derivatives as hepatitis hcv inhibitors
10/27/16Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors
10/20/16Lxr modulators
10/20/16Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn-alpha responses
10/20/16Par4 agonist peptides
10/20/16Compositions comprising a combination of an anti-pd-1 antibody and another antibody
10/13/16Dihydropyrazole gpr40 modulators
10/13/16Inhibitors of lysine methyl transferase
10/13/16Inhibitors of lysine methyl transferase
10/13/16Inhibitors of type 2 vascular endothelial growth factor receptors
10/06/16Ido inhibitors
10/06/16Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
10/06/16Substituted pyridine derivatives useful as gsk-3 inhibitors
Social Network Patent Pack
10/06/16Lxr modulators
09/29/16Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
09/29/16Dihydropyrazole gpr40 modulators
09/29/16Pyrrolidine gpr40 modulators
09/22/16Gsk-3 inhibitors
09/22/16Immunomodulators
09/22/16Treatment of c1013g/cxcr4-associated waldenstrÖm's macroglobulinemia with an anti-cxcr4 antibody
09/22/16Diagnostic methods for par4 antagonist therapy
09/15/16Apixaban liquid formulations
09/15/16Stable subcutaneous protein formulations and uses thereof
Patent Packs
09/15/16Cyclic protein tyrosine kinase inhibitors
09/15/16Gdf-8 inhibitors
09/15/16Tubulysin compounds, methods of making and use
09/15/16Immunotherapeutic dosing regimens and combinations thereof
09/08/16Dihydropyridinone mgat2 inhibitors
09/08/16Radioligands for imaging the lpa-1 receptor
09/08/16Inhibitors of human immunodeficiency virus replication
09/08/16Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
09/08/16Tgf-beta inhibitors
09/08/16Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
09/01/16Bicyclic compounds
08/25/16Apixaban formulations
08/25/16Pyrrolotriazine kinase inhibitors
08/18/16Oxazolidinones as modulators of mglur5
08/18/16Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders
08/18/16Methods for the selection of binding proteins
08/18/16Tau antisense oligomers and uses thereof
08/11/16Rorgamma modulators
08/11/16Process for the preparation of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide
08/11/16Human fc-bearing igg antibodies to polyethylene glycol
08/04/16Aryl ether-base kinase inhibitors
08/04/16Immunomodulators
08/04/16Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
07/21/16Benzoquinolone inhibitors of vmat2
07/14/16Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
07/14/16Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
07/14/16Ido inhibitors
07/14/16Carbazole carboxamide compounds
07/14/16Imidazole-derived modulators of the glucocorticoid receptor
07/14/16Benzodiazepine dimers, conjugates thereof, and methods of making and using
Patent Packs
07/07/16Therapeutic trem-1 peptides
07/07/16Compounds useful as immunomodulators
07/07/16Substituted tetrahydrocarbazole and carbazoles carboxamide compounds
06/30/16Injection aid for use with an injection device and use
06/30/16Imide and acylurea derivatives as modulators of the glucocorticoid receptor
06/30/16Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
06/23/16Immunomodulators
06/23/16Novel tricyclic compounds as anticancer agents
06/23/16Tgf beta r antagonists
06/23/16Immunomodulators
06/23/16Antibodies to tigit
06/16/16Combinations comprising biphenyl derivatives for use in the treatment of hcv
06/16/16Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis c virus
06/09/16Combinations of hepatitis c virus inhibitors
06/09/16Methods for treating scleroderma by administering a soluble ctla4 molecule
06/09/16Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions
06/09/16Pyrimidine compounds for the treatment of hepatitis c
06/09/16Fibronectin based scaffold domain proteins that bind pcsk9
06/02/16Compositions having c-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
06/02/16Prodrugs of substituted azaindoleoxoacetic piperazine derivatives
Social Network Patent Pack
06/02/16Aryl lactam kinase inhibitors
06/02/16Tricyclic pyrido-carboxamide derivatives as rock inhibitors
06/02/16Tricyclic pyrido-carboxamide derivatives as rock inhibitors
06/02/16Methods for the preparation of hiv attachment inhibitor piperazine prodrug compound
06/02/16Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
06/02/16Targeted therapeutics based on engineered proteins that bind egfr
06/02/16Combination therapy for cancer
06/02/16Methods for identifying patients at risk for costimulation blockade resistant rejection
05/26/16Ido inhibitors
05/26/16Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
05/26/16Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
05/26/16Antibodies against cd73 and uses thereof
05/19/16Ido inhibitors
05/19/16Immunomodulators
05/12/16Tert-butyl sulphoxide producing festinavir
05/12/16Crystalline forms of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide for the treatment of myeloproliferative disorders
05/12/16Tubulysin analogs and methods of making and use
05/05/16Novel substituted pyrazolo-piperazines as casein kinase 1 d/e inhibitors
04/28/16Indole carboxamide compounds
04/28/16Macrocyclic factor viia inhibitors
Social Network Patent Pack
04/28/16Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
04/28/16Modified fgf-21 polypeptides and uses thereof
04/21/16Methods for the preparation of hiv attachment inhibitor piperazine prodrug compound
04/21/16Imidazotriazinecarbonitriles useful as kinase inhibitors
04/14/16Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
04/14/16Co-processing method and formulation for hiv attachment inhibitor prodrug compound and excipients
04/07/16Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
04/07/16Pyrimidinones as factor xia inhibitors
04/07/16Substituted bicyclic heteroaryl compounds
03/31/16Phthalazinones and isoquinolinones as rock inhibitors
03/31/16Crystalline forms of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide for the treatment of myeloproliferative disorders
03/31/16Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
03/24/16Selective nr2b antagonists
03/24/16Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
03/17/16Substituted azaindoleoxoacetic piperazine derivatives
03/17/16Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
03/17/16Antibody polypeptides that antagonize cd40l
03/10/16Hepatitis c virus inhibitors
03/10/16Hepatitis c virus inhibitors
03/10/16Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
03/10/16Novel macrocycles as factor xia inhibitors
03/03/16Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
03/03/16Ido inhibitors
03/03/165-methyluridine producing festinavir
02/25/16Substituted bicyclic compounds
02/25/16Piperazine and homopiperazine derivatives as hiv attachment inhibitors
02/25/162-keto amide derivatives as hiv attachment inhibitors
02/11/16Hiv treatment formulation of atazanavir and cobicistat
02/11/16Bicyclo [2.2.2] acid gpr120 modulators
02/11/16Process for the preparation of 4-(8-(2-chlorophenoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)bicyclo[2.2.1]heptan-1-ol and novel intermediates therefor
Social Network Patent Pack
02/11/16Inhibitors of human immunodeficiency virus replication
02/04/16(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
02/04/16Aryl dihydropyridinones and piperidinone mgat2 inhibitors
02/04/16Immunoassay standards and measurement of tau using intra-assay calibration standards
01/28/16Inhibitors of indoleamine 2,3-dioxygenase (ido)
01/28/16Processes for preparing tetrahydroisoquinolines
01/28/16Combination therapy for the treatment of proliferative diseases
01/28/16Inhibitors of human immunodeficiency virus replication
01/28/16Fused furans for the treatment of hepatitis c
01/28/16Compounds for the treatment of hepatitis c
01/28/16Methods of producing antibodies in yeast
01/28/16Methods for producing antibodies
01/21/16Bicyclo [2.2.1] acid gpr120 modulators
01/21/16Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
01/21/16Spirocycloheptanes as inhibitors of rock
01/21/16Isoquinolines as potassium ion channel inhibitors
01/21/16Inhibitors of human immunodeficiency virus replication
01/21/16Pyrrolopyridazines as potassium ion channel inhibitors
01/21/16Aryl amide-based kinase inhibitors
01/14/16Carbazole compounds useful as bromodomain inhibitors
01/14/16Pyrrolotriazines as potassium ion channel inhibitors
01/07/16Inhibitors of human immunodeficiency virus replication
01/07/16Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
01/07/16Inhibitors of human immunodeficiency virus replication
01/07/16High ph protein refolding methods
12/31/15Tangential flow filtration based protein refolding methods
12/31/15Hepatitis c virus inhibitors
12/24/15Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
12/24/15Macrocyclic molecules as hcv entry inhibitors







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Bristol myers Squibb Company in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bristol myers Squibb Company with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';